ArticleExploration of targeted anti-tumor therapy2026
Oncologic outcome and safety profile of first-line enfortumab vedotin plus pembrolizumab vs. conventional chemotherapy in advanced urothelial cancer.
Makito Miyake et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.